GIP Hormone Reduces Excess Androgen Production in Polycystic Ovary Syndrome Models
Glucose-dependent insulinotropic peptide (GIP) significantly suppressed testosterone production in PCOS mouse models and cell systems, suggesting a new therapeutic angle for hyperandrogenism.
Quick Facts
What This Study Found
GIP significantly reduced testosterone secretion in PCOS mouse models and NCI-H295R cells, suppressing androgen biosynthesis through specific molecular pathways identified via RNA sequencing.
Key Numbers
- GIP significantly reduced testosterone in PCOS mice
- Downregulated GIPR, STAR, CYP11A1, and CYP17A1 in ovarian cells
- PSENEN was the most downregulated gene on RNA-seq
- PSENEN knockdown further reduced testosterone production
How They Did This
Combined in vivo (DHEA-induced PCOS mouse model) and in vitro (NCI-H295R adrenal cell line) study using CCK8, flow cytometry, RT-qPCR, Western blot, ELISA, and RNA-seq to assess GIP's effects on androgen synthesis.
Why This Research Matters
PCOS affects up to 13% of women of reproductive age, and hyperandrogenism is its most distressing feature. Current anti-androgen treatments have significant limitations. GIP-based therapies could offer a new approach, especially given the growing availability of GIP-containing drugs like tirzepatide.
The Bigger Picture
With tirzepatide (a dual GIP/GLP-1 agonist) already on the market, these findings suggest an unexpected benefit for women with PCOS. This could accelerate clinical investigation of tirzepatide and similar drugs for PCOS management.
What This Study Doesn't Tell Us
Animal model — DHEA-induced PCOS may not fully represent human PCOS pathophysiology; NCI-H295R cells are an adrenal cancer cell line, not normal ovarian tissue; dose-response relationships not fully characterized; no human clinical data.
Questions This Raises
- ?Would tirzepatide (a dual GIP/GLP-1 agonist) have anti-androgenic benefits in women with PCOS?
- ?Does GIP suppress androgens through ovarian or adrenal pathways, or both?
- ?Could GIP agonism complement existing anti-androgen therapies for PCOS?
Trust & Context
- Key Stat:
- Significant testosterone reduction GIP suppressed androgen biosynthesis in both PCOS mouse models and human adrenal cell cultures
- Evidence Grade:
- Preclinical study combining animal and cell models with comprehensive molecular characterization. Strong mechanistic evidence but no human data yet.
- Study Age:
- Published in 2025, timely given the rapid expansion of GIP-containing medications like tirzepatide.
- Original Title:
- Glucose-dependent insulinotropic peptide (GIP) suppresses androgen biosynthesis in PCOS mouse models and cellular systems.
- Published In:
- Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 41(1), 2582506 (2025)
- Authors:
- Pan, Mengru, Qian, Yifan, Jiang, Linlin(2), Cao, Chunwei, Li, Lin
- Database ID:
- RPEP-12929
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is GIP and how is it related to GLP-1 drugs?
GIP (glucose-dependent insulinotropic peptide) is a gut hormone similar to GLP-1. Both help regulate insulin and blood sugar. The drug tirzepatide activates both GIP and GLP-1 receptors, and this study suggests GIP activation may also help reduce excess androgen production.
Could weight loss drugs help with PCOS?
This study suggests GIP may directly suppress androgen production, independent of weight loss. Since PCOS involves excess androgens causing symptoms like acne, excess hair growth, and fertility problems, GIP-based drugs could potentially address these symptoms through a new mechanism.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12929APA
Pan, Mengru; Qian, Yifan; Jiang, Linlin; Cao, Chunwei; Li, Lin. (2025). Glucose-dependent insulinotropic peptide (GIP) suppresses androgen biosynthesis in PCOS mouse models and cellular systems.. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 41(1), 2582506. https://doi.org/10.1080/09513590.2025.2582506
MLA
Pan, Mengru, et al. "Glucose-dependent insulinotropic peptide (GIP) suppresses androgen biosynthesis in PCOS mouse models and cellular systems.." Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2025. https://doi.org/10.1080/09513590.2025.2582506
RethinkPeptides
RethinkPeptides Research Database. "Glucose-dependent insulinotropic peptide (GIP) suppresses an..." RPEP-12929. Retrieved from https://rethinkpeptides.com/research/pan-2025-glucosedependent-insulinotropic-peptide-gip
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.